PASG (Passage Bio) Total Liabilities: $24.71 Mil (As of Mar. 2026)


PASG Passage Bio Inc PASG
30 GF Score
Price $4.63
! 2 Warning Signs
View Full Analysis

What is Passage Bio Total Liabilities?

Passage Bio PASG +2.18% 30 Total Liabilities is $24.71 Mil as of Mar. 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Passage Bio's Total Liabilities for the quarter that ended in Mar. 2026 was $24.71 Mil.

Passage Bio's quarterly Total Liabilities increased from Sep. 2025 ($43.04 Mil) to Dec. 2025 ($43.53 Mil) but then declined from Dec. 2025 ($43.53 Mil) to Mar. 2026 ($24.71 Mil).

Passage Bio's annual Total Liabilities increased from Dec. 2023 ($39.26 Mil) to Dec. 2024 ($41.15 Mil) and increased from Dec. 2024 ($41.15 Mil) to Dec. 2025 ($43.53 Mil).

Passage Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Passage Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Passage Bio Total Liabilities Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 36.42 42.18 39.26 41.15 43.53

Passage Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.30 40.94 43.04 43.53 24.71
PASG
30GF Score
Passage Bio Inc PASG
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Passage Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=23.083+(20.443+3.5527136788005E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=43.53

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=62.281-18.755
=43.53

Passage Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=20.104+(4.606+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=24.71

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=36.462-11.752
=24.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $24.71 Mil mean?
Passage Bio (PASG) has a Total Liabilities of $24.71 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Passage Bio and its competitors.
Is Passage Bio's Total Liabilities too high?
Passage Bio's current Total Liabilities is $24.71 Mil. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Total Liabilities compare to CTXR and HIND?
Passage Bio's Total Liabilities of $24.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Passage Bio and its competitors. Passage Bio's current Total Liabilities is $24.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Total Liabilities of $24.71 Mil. The current Total Liabilities is $24.71 Mil. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Passage Bio (PASG), the current Total Liabilities is $24.71 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price